-
公开(公告)号:WO2022159594A1
公开(公告)日:2022-07-28
申请号:PCT/US2022/013146
申请日:2022-01-20
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: PARENT, Stephan D. , JOHNSON, Courtney S. , KINCAID, John
IPC: A61K31/16 , A61K31/4353 , A61K31/437 , C07D471/00 , C07D471/02 , C07D471/04
Abstract: The present disclosure provides crystalline forms of the compound having formula (I): (I), wherein the crystalline forms are crystalline Forms A, B, C, E, F, and H, each of which is characterized by an X-ray powder diffraction (XRPD) pattern. The present disclosure also provides methods for preparing crystalline forms, in particular Form A. The present disclosure further provides methods of treating various skin disorders using the crystalline forms of the disclosure or a pharmaceutical composition thereof.
-
公开(公告)号:WO2020106304A1
公开(公告)日:2020-05-28
申请号:PCT/US2019/000066
申请日:2019-11-20
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: KINCAID, John , NEWSAM, John , KISAK, Edward , WOOTTON, Michael , KUSHWAHA, Avadhesh
IPC: A61K31/166 , A61K47/38 , A61K9/06
Abstract: Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.
-
公开(公告)号:WO2018213807A1
公开(公告)日:2018-11-22
申请号:PCT/US2018/033544
申请日:2018-05-18
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: KINCAID, John , DUNCTON, Matthew
IPC: A61K31/4365 , A61K31/4355 , C07D495/04 , C07D491/04 , A61P35/00
Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R 1 , R 2 , R 2a , R 3 , R 3a , and R 3b are as described herein.
-
公开(公告)号:WO2022159600A1
公开(公告)日:2022-07-28
申请号:PCT/US2022/013153
申请日:2022-01-20
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: HOUGHTON, Michael , KINCAID, John
IPC: A61K31/435 , A61K31/4353 , A61K31/437 , C07D471/00 , C07D471/02 , C07D471/04
Abstract: The present disclosure provides processes for preparing a compound of formula (I) from a compound of formula (II) via two steps: 6a) contacting 2-(aminooxy)ethanol (i.e., formula (K)) or a salt thereof (e.g., formula (K-1)), with a base and a silylating agent to form a first mixture including an O-silyl protected compound of formula (K); and 6b) adding a second mixture including a compound of formula (II) or a salt therefore, to the first mixture of step 6a) to form the compound represented by formula (I): The present processes only utilize less than 1.5 equivalents of 2-(aminooxy)ethanol or the salt thereof relative to the compound of formula (II), and therefore reduce the burden to remove excess 2-(aminooxy)ethanol on a large manufacturing scale. Also provided are processes for preparing the compound of formula (K) or (K-1).
-
公开(公告)号:WO2020106303A1
公开(公告)日:2020-05-28
申请号:PCT/US2019/000065
申请日:2019-11-20
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: TSAI, Kenneth, Y. , KINCAID, John , SARIN, Kavita, Yang
IPC: A61K31/136 , A61K31/192 , A61P35/00
Abstract: Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X 1 , X 2 , X 3 , R 1 , R 2 , R 2a , R 13 , R l3a , R 23 , R 23a , R 23b , R 33 , R 33a , R 33b , R 43 , R 43a , R 51 , R 53 , R 53a , R 53b , bond "a", and subscript n are described herein.
-
公开(公告)号:WO2020106307A1
公开(公告)日:2020-05-28
申请号:PCT/US2019/000069
申请日:2019-11-20
Applicant: NFLECTION THERAPEUTICS, INC. , THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventor: KINCAID, John , SARIN, Kavita, Yang
IPC: A61K31/136 , A61K31/166 , A61P17/00
Abstract: Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (1), (II), (III), (IV), and (V). wherein X 1 , X 2 , X 3 , R 1 , R 2 , R 2a , R 13 , R 13a , R 23 , R 23a , R 23b , R 33 , R 33a , R 33b , R 43 , R 43a , R 51 , R 53 , R 53a , R 53b , bond "a", and subscript n are described herein.
-
公开(公告)号:WO2020106305A1
公开(公告)日:2020-05-28
申请号:PCT/US2019/000067
申请日:2019-11-20
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: KINCAID, John , DUNCTON, Matthew
IPC: A61K31/381 , C07D333/38 , A61P35/00
Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R 1 , R 2 , R 2a , R 3 , and R 3a are as described herein.
-
公开(公告)号:WO2018213810A1
公开(公告)日:2018-11-22
申请号:PCT/US2018/033547
申请日:2018-05-18
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: KINCAID, John , DUNCTON, Matthew
IPC: A61K31/437 , C07D471/04 , A61P35/00
Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X 1 , R 1 , R 2 , R 2a , R 3 , R 3a , and R 3b are as described herein.
-
公开(公告)号:WO2022066875A1
公开(公告)日:2022-03-31
申请号:PCT/US2021/051710
申请日:2021-09-23
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: POWALA, Christopher , PLOTKIN, Scott , SARIN, Kavita , MOREFIELD, Elaine , SHAHRYARI, Jahanbanoo , FENN, Peter
IPC: A61K31/437 , C07D471/04 , A61P35/00
Abstract: Provided herein are nasal spray formulations including a compound of formula (I) and methods of using these nasal spray formulations for the treatment of ADHD, or a cognitive dysfunction disease or disorder in a subject having a neurofibromatosis. In some embodiments, the neurofibromatosis is neurofibromatosis type-1, neurofibromatosis type-2, or schwannomatosis. Compounds of formula (I) are represented by (I), wherein R1, R2, R2a, R3, R3a, and R3b are as defined and described herein.
-
公开(公告)号:WO2020106308A1
公开(公告)日:2020-05-28
申请号:PCT/US2019/000070
申请日:2019-11-20
Applicant: NFLECTION THERAPEUTICS, INC.
Inventor: KINCAID, John , DUNCTON, Matthew
IPC: A61K31/4375 , A61P9/06 , C07D471/04
Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R 1 , R 2 , R 2a , R 3 , R 3a , R 3b , and subscript n are as described herein.
-
-
-
-
-
-
-
-
-